Promising drug may halt devastating NMOSD attacks faster
NCT ID NCT07184840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether eculizumab can help people having a sudden attack of NMOSD, a rare autoimmune disease that damages the nerves in the eyes and spine. The drug works by blocking part of the immune system to stop nerve injury. About 110 adults who test positive for a specific antibody will receive the drug, and doctors will measure if their disability improves within 28 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.